PFE News
Pfizer Inc.
$29.21
+$0.84(+2.96%)
70
Overall
100
Value
63
Tech
47
Quality
Market Cap
$161.70B
Volume
39.31M
52W Range
$23.62 - $29.21
Target Price
$29.46
PFE news: the latest Pfizer Inc. headlines, press releases and market updates, newest first.
Latest PFE News
- Pfizer’s Next‑Gen Pneumococcal Shot Enters Key Phase 3 Test, Extending Vaccine Growth PotentialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 14, 2026
- Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)TipRanks Newsroom · Oct 13, 2026
- Analysts Offer Insights on Healthcare Companies: Cogstate Ltd (OtherCOGZF) and Pfizer (PFE)TipRanks Newsroom · Oct 13, 2026
- Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)TipRanks Newsroom · Oct 12, 2026
- Pfizer (PFE) Ramps Up Three Phase 3 Trials, Tempting BullsTipRanks Weekend Auto-Generated Newsdesk · Oct 10, 2026
- Pfizer’s New RSV Vaccine Trial Targets Older Adults, Signaling Long-Term Growth PotentialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 9, 2026
- Pfizer’s New Asthma Bet: Tilrekimig Phase 3 Trial Moves ForwardTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 9, 2026
- J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Oct 9, 2026
- DBS Keeps Their Buy Rating on Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Oct 8, 2026
- Pfizer’s VESPER-OSA 1 Trial Targets Sleep Apnea and Obesity With Monthly ShotTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- Pfizer (PFE) Receives a Hold from Berenberg BankTipRanks Auto-Generated Intelligence Newsdesk · Oct 7, 2026
- BioTech TRex Bio Set to Roar Onto Nasdaq With $133M IPODavid Craik · Oct 5, 2026
- Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Genmab (GMAB)TipRanks Newsroom · Oct 5, 2026
- Pfizer (PFE) Quietly Builds New Cancer And RSV PowerhouseTipRanks Weekend Auto-Generated Newsdesk · Oct 3, 2026
- Pfizer (PFE) Receives a Hold from Leerink PartnersTipRanks Auto-Generated Intelligence Newsdesk · Oct 3, 2026
- Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key MilestoneTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 2, 2026
- Jefferies Sticks to Their Buy Rating for Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Oct 2, 2026
- UBS Sticks to Their Hold Rating for Pfizer (PFE)TipRanks Auto-Generated Intelligence Newsdesk · Oct 2, 2026
- Pantera Minerals Emphasises Disciplined Exploration Strategy and Data CaveatsTipRanks Australian Auto-Generated Newsdesk · Sep 30, 2026
- Pantera Minerals Buys Low-Cost Corona Gold Project in Albany Fraser OrogenTipRanks Australian Auto-Generated Newsdesk · Sep 29, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PFE | $29.21 | +3.0% | 39.31M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |